Microbiome & Live Biotherapeutic CDMO Services

Microbiome products bring living systems into manufacturing.

That changes the work. The product is not always a purified molecule. It can be a live strain, engineered microbe, microbial consortium, spore-forming organism, phage product, postbiotic material, microbial metabolite, or oral live biotherapeutic built around viability, identity, activity, stability, and delivery.

These products require a CDMO route that understands microbiology, fermentation, strain control, anaerobic handling, formulation, drying, storage, release testing, and quality documentation.

A live biotherapeutic product does not succeed because the organism grows in a flask. It succeeds when the correct strain or consortium can be produced, stabilized, tested, stored, shipped, and delivered in a form that preserves the intended biological behavior.

CDMO Network supports microbiome and live biotherapeutic programs across strain banking, microbial fermentation, anaerobic manufacturing, biomass recovery, identity testing, purity testing, potency or activity testing, consortium control, spore processing, lyophilization, encapsulation, oral dosage support, GMP readiness, stability, and clinical supply planning.

The manufacturing route starts with the biological state of the product.

Is it live?
Is it anaerobic?
Is it engineered?
Is it a single strain or a consortium?
Is it spore-forming?
Is it a phage?

Is the active material a postbiotic or metabolite instead of a live organism?
What has to remain viable, active, defined, and stable?

Those answers shape the process.

Live products need live-product manufacturing logic

Microbiome and live biotherapeutic programs require a different control model from purified biologics.

A monoclonal antibody can be defined by structure, purity, potency, and stability. A live microbial product also needs viable count, strain identity, absence of unwanted organisms, genetic stability where relevant, phenotype, activity, composition, storage behavior, and delivery format.

A consortium adds ratio control.

A strict anaerobe adds oxygen-control pressure.
A spore product adds germination and dormancy questions.
An engineered microbe adds construct stability and containment logic.

A phage product adds host-cell system, titre, endotoxin, and potency concerns.
A postbiotic shifts the focus from viability to composition and biological activity.

The CDMO route must follow those differences.

A live product needs manufacturing that preserves the organism or biological activity the product is built around. A process that delivers biomass but loses viability, function, or strain balance has not solved the problem.

The product has to remain itself.

Strain banking and starting material control

Microbiome programs begin with strain control.

The strain bank, source history, identity method, genetic stability, storage condition, and passage strategy affect the entire manufacturing path. If the starting material is poorly defined, the downstream process inherits that uncertainty.

Support can include master cell bank or strain bank development, working bank preparation, strain identity testing, genomic confirmation, purity testing, contamination control, storage strategy, passage-limit planning, and documentation.

For live biotherapeutics, strain identity is central. For engineered microbes, construct retention and genetic stability matter. For consortia, each strain must remain identifiable and controlled. For strict anaerobes, banking and revival conditions can affect viability and performance.

The starting material is not administrative background.

It is the foundation of the product.

The CDMOs in our Network support microbial programs with the strain-control discipline needed before fermentation, formulation, and release testing begin.

Microbial fermentation and anaerobic manufacturing

Fermentation is the production engine for many microbiome and live biotherapeutic programs.

The process can involve aerobic fermentation, anaerobic fermentation, microaerophilic conditions, spore production, engineered strain production, phage amplification, or controlled growth of microbial consortia.

Upstream development can include media selection, feed strategy, pH control, oxygen control, redox control, temperature strategy, harvest timing, biomass density, metabolite monitoring, contamination prevention, and scale-down modeling.

Anaerobic programs add specialized constraints. Oxygen exposure can reduce viability, alter product behavior, or damage the intended biological state. Strict anaerobes require controlled handling from banking through fermentation, harvest, formulation, filling, storage, and testing.

Consortia add another challenge.

The process must preserve composition. One strain can dominate. Another can decline. Growth rates can diverge. Media conditions can shift the balance. Harvest timing can alter ratios.

Microbial manufacturing succeeds when growth, identity, viability, and composition remain controlled at useful scale.

Biomass recovery, concentration, and stabilization

After fermentation, the product has to survive recovery.

Biomass recovery can include centrifugation, filtration, washing, concentration, buffer exchange, cryoprotection, lyoprotection, drying preparation, or bulk formulation. Each step can affect viability, activity, purity, and stability.

Live organisms can be damaged by shear, osmotic shifts, oxygen exposure, temperature, drying stress, pH changes, or incompatible excipients. Spores require different processing logic than vegetative cells. Phage products require host-cell impurity control and potency preservation. Postbiotic products require composition control rather than viability preservation.

Stabilization can include frozen storage, refrigerated storage, lyophilization, spray drying where appropriate, encapsulation, cryoprotectants, lyoprotectants, oxygen-barrier packaging, moisture control, and oral delivery formulation.

The recovery process should not only collect material.

It has to preserve the biological state that gives the product value.

Formulation, lyophilization, and oral delivery

Microbiome and live biotherapeutic products often depend on formulation.

The product may need to survive manufacturing, storage, shipment, stomach acid, bile exposure, capsule filling, rehydration, or delivery to a specific region of the gastrointestinal tract.

Formulation support can include cryoprotectant screening, lyoprotectant screening, excipient selection, lyophilization cycle development, capsule compatibility, enteric coating strategy, moisture control, oxygen protection, refrigerated or room-temperature storage evaluation, and in-use handling studies.

Lyophilization can preserve viability, but it can also damage cells if the cycle, protectants, residual moisture, or packaging are not appropriate. Encapsulation can improve delivery, but it can also affect moisture, oxygen exposure, release profile, and viability.

For oral live biotherapeutics, the final presentation matters.

A strong fermentation batch can still fail if formulation cannot protect the organism through storage and use.

Identity, purity, viability, and potency testing

Microbiome products need analytical systems that fit living biology.

Testing can include strain identity, genome sequencing, qPCR, ddPCR, plate counts, viable count, total count, purity testing, absence of contaminants, microbial limits, endotoxin where relevant, residual host-cell material where relevant, metabolite analysis, activity assays, potency assays, composition analysis, and stability testing.

A single-strain product needs identity, purity, viability, and stability. A consortium needs strain-level identity and ratio control. An engineered microbe needs genetic stability and function. A spore product needs spore count, germination behavior, and stability. A postbiotic needs composition, activity, and consistency. A phage product needs titre, host-cell impurity control, endotoxin control, sequencing where relevant, and potency.

Potency can be difficult because mechanisms vary.

The product may act through colonization, metabolite production, immune modulation, pathogen inhibition, barrier support, enzymatic activity, or another biological function. The assay strategy has to follow the intended mechanism.

Testing should prove the product’s identity and functional relevance.

Not only count organisms.

Engineered microbes and synthetic communities

Engineered microbes and synthetic microbial communities add design complexity.

They can involve inserted pathways, gene circuits, controlled expression systems, metabolic outputs, kill switches, auxotrophy, containment features, defined consortia, or multi-strain interactions.

Manufacturing has to protect both biology and design intent.

Support can include strain engineering, construct stability testing, fermentation development, containment-aware process planning, genetic identity testing, functional activity assays, metabolite profiling, ratio control, formulation, and stability studies.

Synthetic communities create additional challenges because each strain can behave differently during growth, harvest, storage, and delivery. The product can change if one organism outgrows another or loses viability faster.

The route has to track the community, not just the total biomass.

A defined microbial product has to remain defined.

Phage and bacteriophage products

Phage programs occupy a related but distinct manufacturing category.

They can support therapeutic, research, agricultural, food safety, or industrial applications. Manufacturing usually requires host-cell systems, phage amplification, clarification, purification, concentration, endotoxin reduction where relevant, host-cell impurity control, potency testing, sequencing, formulation, and stability.

A phage product requires titre, specificity, purity, and activity. The host system matters. The purification method matters. Endotoxin can matter depending on use. Stability can change with buffer, temperature, storage, drying, or formulation.

Phage cocktails add mixture complexity.

Each phage may amplify differently, purify differently, and remain stable differently. The final product needs defined composition and consistent potency.

CDMO routing has to understand both microbial production and biologic product control.

Phage manufacturing is not standard fermentation with a different label.

Postbiotics and microbial metabolites

Not every microbiome product is live.

Postbiotics, microbial metabolites, conditioned media, lysates, secreted factors, and fermentation-derived bioactive materials shift the manufacturing focus from viability to composition and activity.

These products can require fermentation control, biomass removal, lysis where intended, purification or concentration, metabolite profiling, activity testing, impurity control, formulation, stability, and quality documentation.

The central question changes.

For live products, viability often matters. For postbiotics, the active composition matters. For metabolites, concentration, purity, and bioactivity matter. For lysates, preparation method, composition, and consistency matter.

The production route has to define what the product actually is.

A postbiotic cannot rely on vague fermentation language.

It needs identity, composition, functional readouts, and reproducible manufacturing.

Quality systems and GMP readiness

Microbiome and live biotherapeutic programs need quality systems that match intended use.

Some products support research, nutrition, wellness, agriculture, food, or industrial use. Others move toward clinical live biotherapeutic development. The quality path changes accordingly.

Support can include batch records, strain bank documentation, raw material control, environmental monitoring where relevant, contamination control, deviation handling, change control, COAs, release testing, supplier qualification, quality agreements, stability records, audit preparation, and GMP readiness.

Clinical live biotherapeutic programs require stronger documentation, defined starting materials, controlled manufacturing, release criteria, validated or qualified methods, stability programs, and regulatory CMC support.

Nutrition or food-related microbial products need a different quality model, but they still need traceability, safety-aware production, consistency, and customer documentation.

The quality level follows the destination.

The product’s use determines how much control the system must carry.

Scale-up and clinical or commercial supply

Microbiome and live biotherapeutic products can behave differently as scale increases.

Growth kinetics shift. Oxygen control becomes harder. Heat transfer changes. Mixing changes. Strain ratios can drift. Harvest timing becomes more important. Drying behavior can change. Viability loss can increase. Packaging and storage conditions can affect shelf life.

Scale-up support can include fermentation scale planning, anaerobic handling design, biomass recovery, formulation transfer, lyophilization scale-up, capsule or dosage-form planning, method transfer, lot comparison, stability studies, and supply strategy.

Clinical supply adds release timing, stability placement, labeling, storage, shipment, site handling, and accountability. Commercial supply adds routine manufacturing, supplier continuity, inventory planning, and cost discipline.

Scale-up does not only mean more organisms.

It means preserving identity, viability, function, and product definition at larger volume.

Microbioomproducten en levende biotherapeutica vragen om productie die identiteit, levensvatbaarheid, samenstelling, activiteit en stabiliteit beschermt. Een enkelvoudige bacteriestam, een strikt anaeroob organisme, een microbiële consortium, een sporenproduct, een faag of een postbioticum heeft telkens een andere controlestrategie. De productieroute verbindt strain banking, fermentatie, anaerobe verwerking, biomassaterugwinning, formulering, lyofilisatie, QC-testen, stabiliteit en kwaliteitsdocumentatie met het beoogde gebruik van het product.

Industry Fit

Microbiome and live biotherapeutic teams use this support when they need controlled microbial production, formulation, testing, and supply.

This includes live biotherapeutic developers, microbiome therapeutic companies, probiotic technology teams, engineered microbe programs, anaerobe developers, phage groups, synthetic community platforms, spore-based product teams, postbiotic companies, microbial metabolite developers, nutrition-focused microbiome brands, and clinical LBP programs.

The work supports strain banking, fermentation, anaerobic processing, biomass recovery, formulation, lyophilization, encapsulation, identity testing, viability testing, composition control, stability, GMP readiness, and clinical or commercial supply.

Microbiome CDMO strategy starts with biological state.

Is the product live, inactive, engineered, anaerobic, spore-forming, phage-based, metabolite-based, or consortium-based?
What must remain viable or active?
What defines identity?
What controls composition?
What storage condition preserves function?
What quality level fits the final use?

Those answers define the manufacturing route.

Requirements for high-quality microbiome and live biotherapeutic CDMO services

A strong microbiome CDMO strategy starts with the organism, biological state, intended use, quality level, formulation requirement, stability target, and supply path.

Support includes strain banking, microbial fermentation, anaerobic manufacturing, biomass recovery, engineered microbe production, microbial consortium processing, spore product support, phage manufacturing, postbiotic production, metabolite-focused workflows, identity testing, viability testing, potency or activity assays, lyophilization, encapsulation, stability studies, quality documentation, GMP readiness, and clinical supply planning.

Single-strain live products need identity, purity, viable count, stability, and controlled storage.

Consortia need strain-level identity, ratio control, and composition stability.

Strict anaerobes need oxygen-controlled handling across production, recovery, formulation, and testing.

Phage programs need host-cell control, titre, potency, impurity reduction, and formulation stability.

Postbiotic and metabolite programs need composition control, activity testing, and reproducible processing.

Microbiome manufacturing succeeds when the product remains defined, stable, and biologically relevant from strain bank through final use.

Email our team at info@cdmonetwork.com